<li>acebutolol<p>acebutolol increases and furosemide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>aceclofenac<p>aceclofenac increases and furosemide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>acemetacin<p>acemetacin increases and furosemide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>albuterol<p>albuterol and furosemide both decrease  serum potassium. Use Caution/Monitor.</p></li><li>aldesleukin<p>aldesleukin increases effects of furosemide by pharmacodynamic synergism. Use Caution/Monitor. Risk of hypotension.</p></li><li>aliskiren<p>aliskiren decreases levels of furosemide by unspecified interaction mechanism. Use Caution/Monitor.</p></li><li>amifostine<p>amifostine increases effects of furosemide by pharmacodynamic synergism. Use Caution/Monitor. Risk of hypotension.</p></li><li>amiloride<p>amiloride increases and furosemide decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.</p></li><li>amphetamine<p>amphetamine decreases effects of furosemide by pharmacodynamic antagonism. Use Caution/Monitor.</p></li><li>arformoterol<p>arformoterol and furosemide both decrease  serum potassium. Use Caution/Monitor.</p></li><li>aspirin<p>aspirin increases and furosemide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>aspirin rectal<p>aspirin rectal increases and furosemide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.  .</p></li><li>aspirin/citric acid/sodium bicarbonate<p>aspirin/citric acid/sodium bicarbonate increases and furosemide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>atenolol<p>atenolol increases and furosemide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>avanafil<p>avanafil increases effects of furosemide by pharmacodynamic synergism. Use Caution/Monitor. Risk of hypotension.</p></li><li>bambuterol<p>bambuterol and furosemide both decrease  serum potassium. Use Caution/Monitor.</p></li><li>beclomethasone, inhaled<p>beclomethasone, inhaled increases toxicity of furosemide by increasing elimination. Use Caution/Monitor. Corticosteroids may increase the hypkalemic effects of loop diuretics.</p></li><li>benazepril<p>benazepril, furosemide. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Risk of acute hypotension, renal insufficiency.</p></li><li>bendroflumethiazide<p>furosemide and bendroflumethiazide both decrease  serum potassium. Use Caution/Monitor.</p></li><li>betaxolol<p>betaxolol increases and furosemide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>bezafibrate<p>bezafibrate, furosemide.
Either increases levels of the other by plasma protein binding competition. Use Caution/Monitor. Increased risk in hypoalbuminemia.</p></li><li>bisoprolol<p>bisoprolol increases and furosemide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>bumetanide<p>bumetanide and furosemide both decrease  serum potassium. Use Caution/Monitor.</p></li><li>cabozantinib<p>furosemide will increase the level or effect of cabozantinib by  Other (see comment). Use Caution/Monitor. MRP2 inhibitors increase cabozantinib toxicity</p></li><li>candesartan<p>candesartan increases and furosemide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>captopril<p>captopril, furosemide. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Risk of acute hypotension, renal insufficiency.</p></li><li>carbenoxolone<p>furosemide and carbenoxolone both decrease  serum potassium. Use Caution/Monitor.</p></li><li>carbidopa<p>carbidopa increases effects of furosemide by pharmacodynamic synergism. Use Caution/Monitor. Therapy with carbidopa, given with or without levodopa or carbidopa-levodopa combination products, is started, dosage adjustment of the antihypertensive drug may be required.</p></li><li>carvedilol<p>carvedilol increases and furosemide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>cefprozil<p>furosemide will increase the level or effect of cefprozil by  acidic (anionic) drug competition for renal tubular clearance. Use Caution/Monitor.</p></li><li>celecoxib<p>celecoxib increases and furosemide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>celiprolol<p>celiprolol increases and furosemide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>chlorothiazide<p>furosemide and chlorothiazide both decrease  serum potassium. Use Caution/Monitor.</p></li><li>chlorthalidone<p>furosemide and chlorthalidone both decrease  serum potassium. Use Caution/Monitor.</p></li><li>cholestyramine<p>cholestyramine decreases levels of furosemide by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>choline magnesium trisalicylate<p>choline magnesium trisalicylate increases and furosemide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.  .</p></li><li>ciprofibrate<p>ciprofibrate, furosemide.
Either increases levels of the other by plasma protein binding competition. Use Caution/Monitor. Increased risk in hypoalbuminemia.</p></li><li>cisplatin<p>furosemide, cisplatin.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Additive ototoxicity.</p></li><li>citalopram<p>furosemide, citalopram. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Possible additive hyponatremia.</p></li><li>cornsilk<p>cornsilk increases effects of furosemide by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of hypokalemia (theoretical interaction).</p></li><li>cyclopenthiazide<p>furosemide and cyclopenthiazide both decrease  serum potassium. Use Caution/Monitor.</p></li><li>cyclosporine<p>cyclosporine increases toxicity of furosemide by Other (see comment). Use Caution/Monitor. 
Comment: Concomitant use of cyclosporine and furosemide is associated with increased risk of gouty arthritis secondary to furosemide-induced hyperurecemia and cyclosporine impairment of renal urate excretion.</p></li><li>deflazacort<p>furosemide and deflazacort both decrease  serum potassium. Use Caution/Monitor.</p></li><li>dichlorphenamide<p>dichlorphenamide and furosemide both decrease  serum potassium. Use Caution/Monitor.</p></li><li>diclofenac<p>diclofenac increases and furosemide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>diflunisal<p>diflunisal increases and furosemide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>digoxin<p>digoxin increases and furosemide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.<span><br><br></span>furosemide increases effects of digoxin by pharmacodynamic synergism. Use Caution/Monitor. Hypokalemia increases digoxin effects.</p></li><li>dobutamine<p>dobutamine and furosemide both decrease  serum potassium. Use Caution/Monitor.</p></li><li>dopexamine<p>dopexamine and furosemide both decrease  serum potassium. Use Caution/Monitor.</p></li><li>drospirenone<p>drospirenone increases and furosemide decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.</p></li><li>empagliflozin<p>empagliflozin, furosemide.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration of empagliflozin with diuretics results in increased urine volume and frequency of voids, which might enhance the potential for volume depletion.</p></li><li>enalapril<p>enalapril, furosemide. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Risk of acute hypotension, renal insufficiency.</p></li><li>ephedrine<p>ephedrine and furosemide both decrease  serum potassium. Use Caution/Monitor.</p></li><li>ephedrine (pulmonary)<p>ephedrine (pulmonary) and furosemide both decrease  serum potassium. Use Caution/Monitor.</p></li><li>epinephrine<p>epinephrine and furosemide both decrease  serum potassium. Use Caution/Monitor.</p></li><li>epinephrine racemic<p>epinephrine racemic and furosemide both decrease  serum potassium. Use Caution/Monitor.</p></li><li>eprosartan<p>eprosartan increases and furosemide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>esmolol<p>esmolol increases and furosemide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>ethacrynic acid<p>ethacrynic acid and furosemide both decrease  serum potassium. Use Caution/Monitor.</p></li><li>etodolac<p>etodolac increases and furosemide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>etoricoxib<p>etoricoxib increases and furosemide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>fenbufen<p>fenbufen increases and furosemide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>fenofibrate micronized<p>fenofibrate micronized, furosemide.
Either increases levels of the other by plasma protein binding competition. Use Caution/Monitor. Increased risk in hypoalbuminemia.</p></li><li>fenofibric acid<p>fenofibric acid, furosemide.
Either increases levels of the other by plasma protein binding competition. Use Caution/Monitor. Increased risk in hypoalbuminemia.</p></li><li>fenoprofen<p>fenoprofen increases and furosemide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>fentanyl<p>fentanyl decreases effects of furosemide by Other (see comment). Modify Therapy/Monitor Closely. 
Comment: Fentanyl can reduce the efficacy of diuretics by inducing antidiuretic hormone release. Fentanyl may also lead to acute urinary retention by causing bladder sphincter spasm (particularly in men with enlarged prostates).</p></li><li>fentanyl intranasal<p>fentanyl intranasal decreases effects of furosemide by Other (see comment). Modify Therapy/Monitor Closely. 
Comment: Fentanyl can reduce the efficacy of diuretics by inducing antidiuretic hormone release. Fentanyl may also lead to acute urinary retention by causing bladder sphincter spasm (particularly in men with enlarged prostates).</p></li><li>fentanyl iontophoretic transdermal system<p>fentanyl iontophoretic transdermal system decreases effects of furosemide by Other (see comment). Modify Therapy/Monitor Closely. 
Comment: Fentanyl can reduce the efficacy of diuretics by inducing antidiuretic hormone release. Fentanyl may also lead to acute urinary retention by causing bladder sphincter spasm (particularly in men with enlarged prostates).</p></li><li>fentanyl transdermal<p>fentanyl transdermal decreases effects of furosemide by Other (see comment). Modify Therapy/Monitor Closely. 
Comment: Fentanyl can reduce the efficacy of diuretics by inducing antidiuretic hormone release. Fentanyl may also lead to acute urinary retention by causing bladder sphincter spasm (particularly in men with enlarged prostates).</p></li><li>fentanyl transmucosal<p>fentanyl transmucosal decreases effects of furosemide by Other (see comment). Modify Therapy/Monitor Closely. 
Comment: Fentanyl can reduce the efficacy of diuretics by inducing antidiuretic hormone release. Fentanyl may also lead to acute urinary retention by causing bladder sphincter spasm (particularly in men with enlarged prostates).</p></li><li>flurbiprofen<p>flurbiprofen increases and furosemide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>formoterol<p>formoterol and furosemide both decrease  serum potassium. Use Caution/Monitor.</p></li><li>fosinopril<p>fosinopril, furosemide. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Risk of acute hypotension, renal insufficiency.</p></li><li>gentamicin<p>furosemide and gentamicin both decrease  serum potassium. Use Caution/Monitor.</p></li><li>hyaluronidase<p>hyaluronidase, furosemide. Other (see comment). Use Caution/Monitor. 
Comment: Drug combination has been found to be incompatible.</p></li><li>hydrochlorothiazide<p>furosemide and hydrochlorothiazide both decrease  serum potassium. Use Caution/Monitor.</p></li><li>ibuprofen<p>ibuprofen increases and furosemide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>imidapril<p>imidapril, furosemide. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Risk of acute hypotension, renal insufficiency.</p></li><li>indacaterol, inhaled<p>furosemide, indacaterol, inhaled. serum potassium. Use Caution/Monitor. Combination may increase risk of hypokalemia.<span><br><br></span>indacaterol, inhaled, furosemide. Other (see comment). Use Caution/Monitor. 
Comment: Caution is advised in the coadministration of indacaterol neohaler with non-potassium-sparing diuretics.</p></li><li>indapamide<p>furosemide and indapamide both decrease  serum potassium. Use Caution/Monitor.</p></li><li>indomethacin<p>indomethacin increases and furosemide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>insulin degludec<p>furosemide decreases effects of insulin degludec by Other (see comment). Use Caution/Monitor. 
Comment: Diuretics may cause hyperglycemia and glycosuria in patients with diabetes mellitus, possibly by diuretic-induced hpokalemia.</p></li><li>insulin degludec/insulin aspart<p>furosemide decreases effects of insulin degludec/insulin aspart by Other (see comment). Use Caution/Monitor. 
Comment: Diuretics may cause hyperglycemia and glycosuria in patients with diabetes mellitus, possibly by diuretic-induced hpokalemia.</p></li><li>insulin inhaled<p>furosemide decreases effects of insulin inhaled by Other (see comment). Use Caution/Monitor. 
Comment: Diuretics may cause hyperglycemia and glycosuria in patients with diabetes mellitus, possibly by diuretic-induced hpokalemia.</p></li><li>irbesartan<p>irbesartan increases and furosemide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>isoproterenol<p>isoproterenol and furosemide both decrease  serum potassium. Use Caution/Monitor.</p></li><li>juniper<p>juniper, furosemide. Other (see comment). Use Caution/Monitor. 
Comment: Juniper may potentiate or interfere with diuretic therapy. Juniper has diuretic effects, but may cause kidney damage at large doses.</p></li><li>ketoprofen<p>ketoprofen increases and furosemide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>ketorolac<p>ketorolac increases and furosemide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>ketorolac intranasal<p>ketorolac intranasal increases and furosemide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.  .</p></li><li>labetalol<p>labetalol increases and furosemide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>levalbuterol<p>levalbuterol and furosemide both decrease  serum potassium. Use Caution/Monitor.</p></li><li>levodopa<p>levodopa increases effects of furosemide by pharmacodynamic synergism. Use Caution/Monitor. Consider decreasing dosage of antihypertensive agent.</p></li><li>lily of the valley<p>furosemide increases toxicity of lily of the valley by Other (see comment). Use Caution/Monitor. 
Comment: Increased risk of cardiac toxicity due to K+ depletion.</p></li><li>lisinopril<p>lisinopril, furosemide. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Risk of acute hypotension, renal insufficiency.</p></li><li>lornoxicam<p>lornoxicam increases and furosemide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>losartan<p>losartan increases and furosemide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>lurasidone<p>lurasidone increases effects of furosemide by Other (see comment). Use Caution/Monitor. 
Comment: Potential  for increased risk of hypotension with concurrent use. Monitor blood pressure and adjust  dose of  antihypertensive agent as needed.</p></li><li>maitake<p>maitake increases effects of furosemide by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of hypokalemia (theoretical interaction).</p></li><li>maraviroc<p>maraviroc, furosemide.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor.</p></li><li>meclofenamate<p>meclofenamate increases and furosemide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>mefenamic acid<p>mefenamic acid increases and furosemide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>meloxicam<p>meloxicam increases and furosemide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>metaproterenol<p>metaproterenol and furosemide both decrease  serum potassium. Use Caution/Monitor.</p></li><li>methyclothiazide<p>furosemide and methyclothiazide both decrease  serum potassium. Use Caution/Monitor.</p></li><li>metolazone<p>furosemide and metolazone both decrease  serum potassium. Use Caution/Monitor.</p></li><li>metoprolol<p>metoprolol increases and furosemide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>moexipril<p>moexipril, furosemide. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Risk of acute hypotension, renal insufficiency.</p></li><li>nabumetone<p>nabumetone increases and furosemide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>nadolol<p>nadolol increases and furosemide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>naproxen<p>naproxen increases and furosemide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>nebivolol<p>nebivolol increases and furosemide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>nitroglycerin rectal<p>nitroglycerin rectal, furosemide.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Observe for possible additive hypotensive effects during concomitant use. .</p></li><li>norepinephrine<p>norepinephrine and furosemide both decrease  serum potassium. Use Caution/Monitor.</p></li><li>olmesartan<p>olmesartan increases and furosemide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>olodaterol inhaled<p>furosemide and olodaterol inhaled both decrease  serum potassium. Use Caution/Monitor.</p></li><li>ombitasvir/paritaprevir/ritonavir<p>ombitasvir/paritaprevir/ritonavir will increase the level or effect of furosemide by  unspecified interaction mechanism. Use Caution/Monitor. Adjust furosemide dose according to individual response,</p></li><li>ombitasvir/paritaprevir/ritonavir &amp; dasabuvir<p>ombitasvir/paritaprevir/ritonavir &amp; dasabuvir will increase the level or effect of furosemide by  unspecified interaction mechanism. Use Caution/Monitor. Adjust furosemide dose according to individual response</p></li><li>ospemifene<p>furosemide, ospemifene.
Either increases levels of the other by plasma protein binding competition. Modify Therapy/Monitor Closely.</p></li><li>oxaprozin<p>oxaprozin increases and furosemide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>parecoxib<p>parecoxib increases and furosemide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>penbutolol<p>penbutolol increases and furosemide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>perindopril<p>perindopril, furosemide. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Risk of acute hypotension, renal insufficiency.</p></li><li>pindolol<p>pindolol increases and furosemide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>pirbuterol<p>pirbuterol and furosemide both decrease  serum potassium. Use Caution/Monitor.</p></li><li>piroxicam<p>piroxicam increases and furosemide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>potassium acid phosphate<p>potassium acid phosphate increases and furosemide decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.</p></li><li>potassium chloride<p>potassium chloride increases and furosemide decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.</p></li><li>potassium citrate<p>potassium citrate increases and furosemide decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.</p></li><li>propranolol<p>propranolol increases and furosemide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>quinapril<p>quinapril, furosemide. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Risk of acute hypotension, renal insufficiency.</p></li><li>ramipril<p>ramipril, furosemide. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Risk of acute hypotension, renal insufficiency.</p></li><li>sacubitril/valsartan<p>sacubitril/valsartan increases and furosemide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>salicylates (non-asa)<p>salicylates (non-asa) increases and furosemide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>salmeterol<p>salmeterol and furosemide both decrease  serum potassium. Use Caution/Monitor.</p></li><li>salsalate<p>salsalate increases and furosemide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>sodium phosphates, iv<p>furosemide decreases effects of sodium phosphates, iv by increasing renal clearance. Modify Therapy/Monitor Closely. Furosemide lowers phosphate serum levels by enhancing renal excretion. Use alternatives if available.</p></li><li>sodium sulfate/potassium sulfate/magnesium sulfate<p>furosemide and sodium sulfate/potassium sulfate/magnesium sulfate both decrease  serum potassium. Modify Therapy/Monitor Closely.</p></li><li>sodium sulfate/potassium sulfate/magnesium sulfate/polyethylene glycol<p>furosemide and sodium sulfate/potassium sulfate/magnesium sulfate/polyethylene glycol both decrease  serum potassium. Modify Therapy/Monitor Closely.</p></li><li>sotalol<p>sotalol increases and furosemide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>spironolactone<p>spironolactone increases and furosemide decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.</p></li><li>succinylcholine<p>succinylcholine increases and furosemide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>sucralfate<p>sucralfate decreases effects of furosemide by inhibition of GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Simultaneous administration of sucralfate and furosemide Injection may reduce the natriuretic and antihypertensive effects of furosemide; patients receiving both drugs should be observed closely to determine if desired diuretic and/or antihypertensive effect of furosemide achieved; intake of furosemide and sucralfate should be separated by at least 2 hr.</p></li><li>sulfasalazine<p>sulfasalazine increases and furosemide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>sulindac<p>sulindac increases and furosemide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>tadalafil<p>tadalafil increases effects of furosemide by pharmacodynamic synergism. Use Caution/Monitor. Risk of hypotension.</p></li><li>telmisartan<p>telmisartan increases and furosemide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>terbutaline<p>terbutaline and furosemide both decrease  serum potassium. Use Caution/Monitor.</p></li><li>timolol<p>timolol increases and furosemide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>tobramycin inhaled<p>tobramycin inhaled, furosemide.
Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Avoid concurrent use if possible; theorized mechanisms include rapid injection of loop diuretics, existing renal impairment, or volume depletion leading to increased aminoglycoside concentration within the nephron.</p></li><li>tolfenamic acid<p>tolfenamic acid increases and furosemide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>tolmetin<p>tolmetin increases and furosemide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>tolvaptan<p>tolvaptan increases and furosemide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>torsemide<p>furosemide and torsemide both decrease  serum potassium. Use Caution/Monitor.</p></li><li>trandolapril<p>trandolapril, furosemide. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Risk of acute hypotension, renal insufficiency.</p></li><li>triamterene<p>triamterene increases and furosemide decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.</p></li><li>trientine<p>furosemide decreases levels of trientine by increasing renal clearance. Use Caution/Monitor.</p></li><li>umeclidinium bromide/vilanterol inhaled<p>umeclidinium bromide/vilanterol inhaled and furosemide both decrease  serum potassium. Modify Therapy/Monitor Closely. Electrocardiographic changes and/or hypokalemia associated with non–potassium-sparing diuretics may worsen with concomitant beta-agonists, particularly if recommended dose is exceeded</p></li><li>valsartan<p>valsartan increases and furosemide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>vilanterol/fluticasone furoate inhaled<p>vilanterol/fluticasone furoate inhaled and furosemide both decrease  serum potassium. Modify Therapy/Monitor Closely. Beta-agonists may acutely worsen ECG changes and/or hypokalemia resulting from non-potassium-sparing diuretics </p></li><li>xipamide<p>xipamide increases effects of furosemide by pharmacodynamic synergism. Use Caution/Monitor.</p></li>